Somatostatin analogs and radiopeptides in cancer therapy.
about
Positron emission tomography imaging of prostate cancerDifferential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cellsMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursAmphiphilic peptides and their cross-disciplinary role as building blocks for nanoscienceTherapeutic cancer targeting peptides.Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesotheliomaDifferential between protein and mRNA expression of CCR7 and SSTR5 receptors in Crohn's disease patients.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications.Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracersEffects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activityNovel synthesis of various orthogonally protected Cα-methyllysine analogues and biological evaluation of a vapreotide analogue containing (S)-α-methyllysine.Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteinsLighting up tumors with receptor-specific optical molecular probes.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Issues related to targeted delivery of proteins and peptides.Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogueFrom somatostatin to octreotide LAR: evolution of a somatostatin analogueSomatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues.Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude miceAntiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase.Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells.Design and evaluation of D-α tocopheryl polyethylene glycol 1000 succinate emulsified poly-ϵ-caprolactone nanoparticles for protein/peptide drug delivery.Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.Molecular Modeling Suggests Conformational Scaffolds Specifically Targeting Five Subtypes of Somatostatin Receptors
P2860
Q24596241-28D44359-59F6-4B21-8605-BC614DB69617Q24812181-D96D9EFD-3214-4323-991F-7BEC9D546444Q26751659-027B6D49-2409-47E7-8468-EAA29E351E7FQ29028236-4CF0D73B-B7F2-42A2-92F8-81858C345E87Q33184888-03BD67E9-E721-4D4B-A636-0F1377716C67Q33555260-63281CB9-D1E0-43AD-B2C7-26CC2CB97980Q33633866-91966470-25D7-4E3B-913F-72BF7E24B190Q33753449-15A2BE6A-F2C3-456B-808D-0FE4E747BFC3Q33793300-06BAD2F7-BB10-4C4F-B2C6-08FD9ECB8235Q34174906-87812904-130C-4DD1-8769-13BF5001A271Q34477028-8186630E-7DD1-4D54-90EC-D95AFCBB971AQ34480119-F14611A1-960E-4792-BA2C-74B00B5DCAB8Q34832716-BA756DC0-4A06-4765-9862-3D4852A18ED7Q34940355-0EB81547-5F16-458A-A16D-32CD66AB4EACQ35666025-3F024CF5-9721-4EDE-8470-30673DAE6DD5Q35843526-86EEC4E6-D91D-440E-AFA9-A92AC38D81A5Q36008285-D4F68DAE-DFFD-4541-A434-7DDB662DBEF0Q36616311-51C47084-E73C-48AE-B879-845D14F5F8E7Q36671779-8456A151-0281-458C-B12E-3897911CC0AFQ36919554-B6AA560C-66BB-4572-B256-725B39677FDFQ37564373-62052E22-009B-4ADF-A2AE-2982A698B5E3Q38502588-ACC2067B-1A48-4274-912A-A15740F264ACQ40031973-3307D8FA-193C-4C40-B995-252E32C48BD5Q40403100-968E63F5-E254-4226-ADA5-71FA2E46F561Q40625583-90349831-9D26-4157-8203-4DE458A3E72AQ42573914-1BDE500F-6726-49D0-A5FD-9FAD2AD769ECQ43617316-CDEE89A7-2E12-4F9B-BE45-C1AA8A513748Q49168467-81D994B4-3D5D-4946-BF3A-F5C61E71624FQ57273387-C361C3D4-7338-4250-851D-92AE422FA3ED
P2860
Somatostatin analogs and radiopeptides in cancer therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Somatostatin analogs and radiopeptides in cancer therapy.
@ast
Somatostatin analogs and radiopeptides in cancer therapy.
@en
Somatostatin analogs and radiopeptides in cancer therapy.
@nl
type
label
Somatostatin analogs and radiopeptides in cancer therapy.
@ast
Somatostatin analogs and radiopeptides in cancer therapy.
@en
Somatostatin analogs and radiopeptides in cancer therapy.
@nl
prefLabel
Somatostatin analogs and radiopeptides in cancer therapy.
@ast
Somatostatin analogs and radiopeptides in cancer therapy.
@en
Somatostatin analogs and radiopeptides in cancer therapy.
@nl
P2860
P356
P1433
P1476
Somatostatin analogs and radiopeptides in cancer therapy.
@en
P2093
Alex N Eberle
Sylvie Froidevaux
P2860
P304
P356
10.1002/BIP.10256
P577
2002-01-01T00:00:00Z